Abstract Programmed cell death ligend-1 (PD-L1) expression by immunohistochemistry (IHC) assays is a predictive marker of anti-PD-1/PD-L1 therapy response. With the popularity of anti-PD-1/PD-L1 inhibitor drugs, quantitative assessment of PD-L1 expression becomes a new labor for pathologists. Manually counting the PD-L1 positive stained tumor cells is an obviously subjective and time-consuming process. In this paper, we developed a new computer aided Automated Tumor Proportion Scoring System (ATPSS) to determine the comparability of image analysis with pathologist scores. A three-stage process was performed using both image processing and deep learning techniques to mimic the actual diagnostic flow of the pathologists. We conducted a multi-...
Immunohistochemistry of the PD-L1 protein may be predictive for anti-PD-1 and anti-PD-L1 immunothera...
BACKGROUND:The anti-programmed death receptor-1 (anti-PD-1) pembrolizumab is approved as first-line ...
Purpose: Reliable and reproducible methods for identifying PD-L1 expression on tumor cells are neces...
Aims Immunohistochemical programmed death-ligand 1 (PD-L1) staining to predict responsiveness to imm...
International audienceBackground: Immune checkpoint therapies (ICTs) targeting the programmed cell d...
AIMS: Immune checkpoint inhibitors have become a successful treatment in metastatic melanoma. The hi...
Abstract Background The programmed death receptor 1 (PD-1) protein is a cell-surface receptor on cer...
A meeting among expert pathologists was held in 2019 in Rome to verify the results of the previous h...
The role of PD-L1 as a prognostic and predictive biomarker is an area of great interest. However, th...
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment ...
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment ...
The role of PD-L1 as a prognostic and predictive biomarker is an area of great interest. However, th...
Assessment of programmed cell death ligand 1 (PD-L1) immunohistochemical staining is used for decisi...
In recent years, the treatment of non-small-cell lung cancer (NSCLC) has been fundamentally changed ...
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment ...
Immunohistochemistry of the PD-L1 protein may be predictive for anti-PD-1 and anti-PD-L1 immunothera...
BACKGROUND:The anti-programmed death receptor-1 (anti-PD-1) pembrolizumab is approved as first-line ...
Purpose: Reliable and reproducible methods for identifying PD-L1 expression on tumor cells are neces...
Aims Immunohistochemical programmed death-ligand 1 (PD-L1) staining to predict responsiveness to imm...
International audienceBackground: Immune checkpoint therapies (ICTs) targeting the programmed cell d...
AIMS: Immune checkpoint inhibitors have become a successful treatment in metastatic melanoma. The hi...
Abstract Background The programmed death receptor 1 (PD-1) protein is a cell-surface receptor on cer...
A meeting among expert pathologists was held in 2019 in Rome to verify the results of the previous h...
The role of PD-L1 as a prognostic and predictive biomarker is an area of great interest. However, th...
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment ...
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment ...
The role of PD-L1 as a prognostic and predictive biomarker is an area of great interest. However, th...
Assessment of programmed cell death ligand 1 (PD-L1) immunohistochemical staining is used for decisi...
In recent years, the treatment of non-small-cell lung cancer (NSCLC) has been fundamentally changed ...
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment ...
Immunohistochemistry of the PD-L1 protein may be predictive for anti-PD-1 and anti-PD-L1 immunothera...
BACKGROUND:The anti-programmed death receptor-1 (anti-PD-1) pembrolizumab is approved as first-line ...
Purpose: Reliable and reproducible methods for identifying PD-L1 expression on tumor cells are neces...